체외 독성 시험 시장 : 제공별, 유형별, 독성 엔드포인트 및 시험별, 기술별, 방법별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The in vitro toxicology testing market is projected to reach USD 20.97 billion by 2031, growing from an estimated USD 12.69 billion in 2026, at a CAGR of 10.6% during the forecast period. Growth is being driven by increasing use of cell-based assays, 3D culture models, organoids, organ-on-chip systems, high-content screening, automation, and AI-enabled predictive toxicology for early-stage compound screening and safety profiling.

The market is further supported by rising pharmaceutical and biotechnology R&D spending, demand for faster and more human-relevant toxicity prediction, outsourcing to CROs, and regulatory momentum to reduce animal testing while improving preclinical decision-making.

"The products segment accounted for a larger share than the services segment in 2025."

By offering, the products segment accounted for the largest share in the global in vitro toxicology testing market. The products segment led the market because in vitro toxicology workflows depend heavily on recurring product consumption, including assay kits, reagents, cell culture media, sera, buffers, microplates, detection substrates, reference standards, and validated cell models. Unlike services, these products are repeatedly required across every cytotoxicity, genotoxicity, organ toxicity, dermal, ocular, and mechanistic toxicity study.

"North America dominated the in vitro toxicology testing market in 2025."

North America dominated the in vitro toxicology testing market in 2025, primarily due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, well-funded academic research centers, and early adoption of non-animal safety testing technologies across the US and Canada. The region has high demand for cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and mechanistic toxicity testing during drug discovery, preclinical development, cosmetics safety assessment, chemical evaluation, and medical device biocompatibility testing. The US also has a mature ecosystem of assay kit suppliers, cell model providers, organ-on-chip companies, high-content screening platforms, and predictive toxicology software developers, supporting broad commercialization of in vitro toxicology products and services. Regulatory modernization initiatives encouraging alternative methods to animal testing further support adoption.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70%; Demand Side 30%
• By Designation: Managers - 45%; CXO & Directors - 30%; and Executives - 25%
• By Region: North America - 40%; Europe - 25%; Asia Pacific - 20%; Latin America - 10%; and Middle East & Africa - 5%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• SGS SA (Switzerland)
• Bio-Rad Laboratories, Inc. (US)
• Evotec SE (Germany)
• Promega Corporation (US)
• Catalent, Inc. (US)
• Agilent Technologies, Inc. (US)
• Intertek Group plc (UK)
• Revvity (US)
• Inotiv (US)
• BioIVT (US)
• Lonza (Switzerland)
• Creative Biolabs (US)
• Shanghai Medicilon Inc. (China)
• Creative Bioarray (US)
• Aragen Life Sciences Ltd. (India)
• Enzo Biochem Inc. (US)
• Microbac Laboratories, Inc. (US)
• Vimta Labs Ltd. (India)
• Pacific BioLabs Inc. (US)
• MB Research Laboratories (US)

Research Coverage:

This research report categorizes the in vitro toxicology testing market by offering {Products [Reagents & Consumables (Cell Lines & Primary Cells, Culture Reagents, Media & Consumables, 3D Models and Tissue Systems, Other Reagents & Consumables), Assay Kits (Cytotoxicity Assay, Genotoxicity Assay, Organ-Specific Toxicity Assay, Other Assays), Equipment (Detection, Imaging & Analytical Systems (Imaging Systems, Detection Instruments, Other Instruments), Liquid Handling & Automation Systems, Other Equipment), Software & Informatics, and Services; Product - By Toxicity End Point (Organ Toxicity Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity and Skin Irritation, Corrosion and Sensitization, Oxidative Stress and Mechanistic Toxicity, Other Toxicity Endpoints and Tests); Product - By Technology (Cell Culture Technologies, High-Throughput and High-Content Technologies, Omics Technologies, Organotypic and Microphysiological Based Technologies, Other Technologies); Product - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Product - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Cros, Academic And Research Institutes, Other End Users); Service- By Type (Toxicology Testing Service, Biological Model And Assay Development Services, Imaging And Analytical Toxicology Services, Data Analysis, Bioinformatics, And Predictive Toxicology); Service - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Service - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Academic And Research Institutes, Other End Users).

The report's scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the in vitro toxicology testing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the in vitro toxicology testing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in vitro toxicology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Growing industry shift toward non-animal toxicology testing methods, increasing technological advancements), restraints (Limited in vivo-to-in vitro correlation for complex endpoints), opportunities (AI/ML-powered predictive toxicology, increasing focus on drug discovery using in vitro methods, cannabis, e-cigarette, and novel product safety testing), and challenges (Ethical and regulatory challenges in AI-driven toxicology), influencing the growth of the market
• Product/Service Development/Innovation: Detailed insights on newly launched products/services of the in vitro toxicology testing market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the in vitro toxicology testing market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US), among others, in the market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW
• 3.2 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE
• 3.3 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing Industry Shift Toward Non-Animal Toxicology Testing Methods
    • 4.2.1.2 Increasing Technological Advancements
    • 4.2.1.3 Rising Pharmaceutical R&D Expenditure and Drug Attrition Costs
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Limited In Vivo-to-In Vitro Correlation for Complex Endpoints
    • 4.2.2.2 High Cost of Advanced Platforms (Organ-on-Chip, 3D Models)
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 AI/ML-Powered Predictive Toxicology
    • 4.2.3.2 Increasing Focus on Drug Discovery Using In Vitro Methods
    • 4.2.3.3 Cannabis, E-Cigarette, and Novel Product Safety Testing
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Ethical and Regulatory Challenges in AI-Driven Toxicology
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL IN VITRO TOXICOLOGY TESTING MARKET
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2025
  • 5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025
• 5.6 KEY CONFERENCES & EVENTS
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT/FUNDING ACTIVITY
• 5.9 IMPACT OF 2025 TARIFFS-IN VITRO TOXICOLOGY TESTING MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 KEY TARIFF RATES
  • 5.9.3 PRICE IMPACT ANALYSIS
  • 5.9.4 IMPACT ON COUNTRIES/REGIONS
    • 5.9.4.1 North America
    • 5.9.4.2 Europe
    • 5.9.4.3 Asia Pacific
  • 5.9.5 IMPACT ON END-USE INDUSTRIES
    • 5.9.5.1 Pharmaceutical and biotechnology companies
    • 5.9.5.2 CROs
    • 5.9.5.3 Academic & Research Institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 CELL CULTURE TECHNOLOGIES
  • 6.1.2 OMICS TECHNOLOGIES
• 6.2 ADJACENT TECHNOLOGIES
  • 6.2.1 COMPUTATIONAL TOXICOLOGY AND AI
• 6.3 COMPLEMENTARY TECHNOLOGIES
  • 6.3.1 LAB-ON-A-CHIP (LOC)/ORGAN-ON-A-CHIP (OOC) SYSTEMS
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN VITRO TOXICOLOGY TESTING PATENTS, 2015-2025
• 6.6 FUTURE APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON IN VITRO TOXICOLOGY TESTING MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET
  • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY TESTING MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 PRODUCTS
  • 9.2.1 GROWING ADOPTION OF ADVANCED ASSAY PRODUCTS TO SUPPORT GROWTH
• 9.3 SERVICES
  • 9.3.1 INCREASING FOCUS ON OUTSOURCING TOXICOLOGY TO AID GROWTH

10 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 REAGENTS & CONSUMABLES
  • 10.2.1 CULTURE REAGENTS, MEDIA, AND CONSUMABLES
    • 10.2.1.1 Increasing adoption of IVTT workflows and recurring use of reagents to support growth
  • 10.2.2 3D MODELS & TISSUE SYSTEMS
    • 10.2.2.1 Support from regulatory agencies and wide usage to drive market growth
  • 10.2.3 CELL LINES & PRIMARY CELLS
    • 10.2.3.1 Emphasis on personalized medicine and driving quality improvement in commercially available cells to propel market
  • 10.2.4 OTHER REAGENTS & CONSUMABLES
• 10.3 ASSAY KITS
  • 10.3.1 ORGAN-SPECIFIC TOXICITY ASSAYS
    • 10.3.1.1 Market is driven well-documented failure of generic cytotoxicity screens to predict organ-level adverse effects
  • 10.3.2 CYTOTOXICITY ASSAYS
    • 10.3.2.1 Cytotoxicity assays are the most universally applied assays in IVTT
  • 10.3.3 GENOTOXICITY ASSAYS
    • 10.3.3.1 Stringent regulatory mandates to support growth
  • 10.3.4 OTHER ASSAYS
• 10.4 EQUIPMENT
  • 10.4.1 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS
    • 10.4.1.1 Detection instruments
      • 10.4.1.1.1 Growth is supported by the increasing volume of HTS workflows in pharmaceutical R&D and expanding use of functional safety pharmacology assays
    • 10.4.1.2 Imaging systems
      • 10.4.1.2.1 Demand for imaging systems in IVTT is being driven by the transition from single-endpoint to multiparametric, image-based toxicity assessment
    • 10.4.1.3 Other instruments
    • 10.4.1.4 Liquid handling & automation systems
      • 10.4.1.4.1 Ease offered by automation and the important role of liquid handling in workflow to aid growth
    • 10.4.1.5 Other instruments
• 10.5 SOFTWARE & INFORMATICS
  • 10.5.1 DEMAND FOR AI/ML CAPABILITIES WITH TOXICOLOGY DATA TO DRIVE GROWTH

11 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST

• 11.1 INTRODUCTION
• 11.2 ORGAN TOXICITY TESTING
  • 11.2.1 HEPATOTOXICITY
    • 11.2.1.1 Regulatory mandates and focus on developing advanced liver models to support growth
  • 11.2.2 OCULAR TOXICITY
    • 11.2.2.1 Demand for cosmetics application to aid growth
  • 11.2.3 CARDIOTOXICITY
    • 11.2.3.1 Regulatory imperative for comprehensive cardiac safety profiling to drive growth
  • 11.2.4 NEUROTOXICITY
    • 11.2.4.1 Focus on developmental neurotoxicity and the expanding CNS drug pipelines to support growth
  • 11.2.5 OTHER TOXICITY END POINTS
• 11.3 CYTOTOXICITY TESTING
  • 11.3.1 A GROWING NUMBER OF NEW CLINICAL ENTITIES AND THE EXPANSION OF HTS PROGRAMS DRIVES MARKET
• 11.4 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION
  • 11.4.1 RISING AWARENESS AND BAN ON ANIMAL TESTING TO PROPEL MARKET
• 11.5 GENOTOXICITY TESTING
  • 11.5.1 MANDATORY REQUIREMENT IN DRUG APPLICATIONS SUPPORTS MARKET GROWTH
• 11.6 OXIDATIVE STRESS AND MECHANISTIC TOXICITY
  • 11.6.1 SHIFT TOWARD MECHANISTIC UNDERSTANDING TO DRIVE DEMAND FOR ASSAYS
• 11.7 OTHER TOXICITY ENDPOINTS & TESTS

12 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY

• 12.1 INTRODUCTION
• 12.2 CELL CULTURE TECHNOLOGIES
  • 12.2.1 ADVANCING ADOPTION OF HUMAN-RELEVANT CELL CULTURE MODELS TO SUPPORT MARKET GROWTH
• 12.3 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES
  • 12.3.1 EXPANDING HIGH-THROUGHPUT TOXICITY SCREENING TO ACCELERATE EARLY SAFETY ASSESSMENT
• 12.4 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES
  • 12.4.1 GROWING FOCUS ON HUMAN-RELEVANT TOXICITY PREDICTION TO SUPPORT GROWTH
• 12.5 OMICS TECHNOLOGIES
  • 12.5.1 INCREASING INTEGRATION OF OMICS-BASED TOXICOLOGY TO IMPROVE MECHANISTIC RISK ASSESSMENT
• 12.6 OTHER TECHNOLOGIES

13 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD

• 13.1 INTRODUCTION
• 13.2 CELL-BASED TOXICITY TESTING
  • 13.2.1 CELL-BASED TOXICITY TESTING HOLDS LARGEST MARKET SHARE
• 13.3 BIOCHEMICAL TOXICITY TESTING METHOD
  • 13.3.1 SPEED AND REPRODUCIBILITY TO AID GROWTH
• 13.4 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD
  • 13.4.1 TRANSITION FROM SINGLE-ENDPOINT TO SYSTEMS-LEVEL TOXICOLOGICAL ASSESSMENT DRIVES DEMAND GROWTH
• 13.5 EX VIVO MODEL-BASED TOXICITY TESTING METHOD
  • 13.5.1 INCREASING AVAILABILITY OF HUMAN DONOR TISSUE TO SUPPORT ADOPTION
• 13.6 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD
  • 13.6.1 ESCALATING COST AND TIME PRESSURES OF PHYSICAL TESTING TO AID GROWTH
• 13.7 OTHER METHODS

14 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER

• 14.1 INTRODUCTION
• 14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 14.2.1 RISING GLOBAL PHARMACEUTICAL R&D EXPENDITURE SUPPORTING DRUG DISCOVERY EFFORTS
• 14.3 CONSUMER CARE COMPANIES
  • 14.3.1 ANIMAL TESTING BANS TO SUPPORT SEGMENT GROWTH
• 14.4 CROS
  • 14.4.1 HIGH CAPITAL AND OPERATIONAL COSTS OF MAINTAINING ADVANCED TECHNOLOGIES SUPPORT OUTSOURCING TO CROS
• 14.5 ACADEMIC & RESEARCH INSTITUTES
  • 14.5.1 INCREASING GOVERNMENT FUNDING FOR ALTERNATIVE TESTING RESEARCH TO AID GROWTH
• 14.6 FOOD & BEVERAGE COMPANIES
  • 14.6.1 GROWTH OF FUNCTIONAL FOODS, PLANT-BASED PROTEINS, AND NOVEL INGREDIENTS DRIVES DEMAND FOR TESTING
• 14.7 OTHER END USERS

15 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE

• 15.1 INTRODUCTION
• 15.2 TOXICOLOGY TESTING SERVICES
  • 15.2.1 ORGAN-SPECIFIC TOXICITY SERVICES
    • 15.2.1.1 High reliance on outsourced services and growing demand for cardiotoxicity testing to drive market
  • 15.2.2 CYTOTOXICITY TESTING SERVICES
    • 15.2.2.1 Growing preclinical pipelines requiring cytotoxicity testing to propel demand
  • 15.2.3 GENOTOXICITY TESTING SERVICES
    • 15.2.3.1 Expanding impurity testing obligations to drive market
  • 15.2.4 OTHER TOXICITY TESTING SERVICES
• 15.3 BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES
  • 15.3.1 STRONG GROWTH SUPPORTED BY RISING DEMAND FOR APPLICATION-SPECIFIC MODELS AND ASSAYS
• 15.4 IMAGING & ANALYTICAL TOXICOLOGY SERVICES
  • 15.4.1 CAPITAL-INTENSIVE INSTRUMENTATION AND SPECIALIZED REQUIREMENTS SUPPORT OUTSOURCING
• 15.5 DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY
  • 15.5.1 INTEGRATION OF AI/ML AND RISING DATA COMPLEXITY PROPEL DEMAND

16 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD

• 16.1 INTRODUCTION
• 16.2 CELL-BASED TOXICITY TESTING SERVICES
  • 16.2.1 HIGH COST AND COMPLEXITY OF MAINTAINING ADVANCED CELL CULTURE INFRASTRUCTURE TO DRIVE GROWTH
• 16.3 BIOCHEMICAL TOXICITY TESTING SERVICES
  • 16.3.1 GROWTH OF BIOLOGIC DRUG DEVELOPMENT IS DRIVING DEMAND FOR SPECIALIZED BIOCHEMICAL IMMUNOGENICITY TESTING SERVICES
• 16.4 IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES
  • 16.4.1 GROWING DATA COMPLEXITY, AI/ML MATURITY, AND REGULATORY ACCEPTANCE DRIVE GROWTH
• 16.5 MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES
  • 16.5.1 SPECIALIZED ANALYTICAL EXPERTISE REQUIREMENTS RELATED TO OMICS TO DRIVE GROWTH
• 16.6 EX VIVO MODEL-BASED TOXICITY TESTING SERVICES
  • 16.6.1 USE OF EX VIVO MODELS FOR IN VITRO AND IN SILICO VALIDATION TO SUPPORT GROWTH
• 16.7 OTHER SERVICES

17 IN VITRO TOXICOLOGY TESTING SERVICE MARKET, BY END USER

• 17.1 INTRODUCTION
• 17.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 17.2.1 INCREASING COST AND COMPLEXITY OF MAINTAINING ADVANCED IVTT PLATFORMS IN-HOUSE TO SUPPORT GROWTH
• 17.3 CONSUMER CARE COMPANIES
  • 17.3.1 REGULATION MANDATING IN VITRO-ONLY SAFETY ASSESSMENT IS SUPPORTING GROWTH
• 17.4 FOOD & BEVERAGE COMPANIES
  • 17.4.1 EXPANDING SCOPE OF FUNCTIONAL FOOD AND ALTERNATIVE PROTEIN SAFETY ASSESSMENT TO SUPPORT GROWTH
• 17.5 ACADEMIC & RESEARCH INSTITUTES
  • 17.5.1 OUTSOURCING OF SPECIALIZED SERVICES TO SUPPORT GROWTH
• 17.6 OTHER END USERS

18 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION

• 18.1 INTRODUCTION
• 18.2 NORTH AMERICA
  • 18.2.1 US
    • 18.2.1.1 Growing focus on biomarker discovery and research in structure-based drug design to propel the market
  • 18.2.2 CANADA
    • 18.2.2.1 Strong support for R&D in pharmaceuticals and proteomics to boost market growth
• 18.3 EUROPE
  • 18.3.1 GERMANY
    • 18.3.1.1 Well-established pharmaceuticals industry to support market growth
  • 18.3.2 UK
    • 18.3.2.1 Rising focus on research activities and academia-industry partnerships to drive market
  • 18.3.3 FRANCE
    • 18.3.3.1 Increasing government funding for proteomics and genomics research to drive market
  • 18.3.4 ITALY
    • 18.3.4.1 Increasing life sciences research to propel market
  • 18.3.5 SPAIN
    • 18.3.5.1 Growing chemicals industry to support market growth
  • 18.3.6 REST OF EUROPE
• 18.4 ASIA PACIFIC
  • 18.4.1 CHINA
    • 18.4.1.1 Increasing international pressure to ban animal testing methods to propel the market
  • 18.4.2 JAPAN
    • 18.4.2.1 Rising demand for technologically advanced research products to drive market
  • 18.4.3 INDIA
    • 18.4.3.1 Growing focus of universities on avoiding animal testing for cosmetic products to propel the market
  • 18.4.4 SOUTH KOREA
    • 18.4.4.1 Growing government focus on boosting pharmaceutical spending to propel market growth
  • 18.4.5 AUSTRALIA
    • 18.4.5.1 Growing pharmaceutical research to help market growth
  • 18.4.6 REST OF ASIA PACIFIC
• 18.5 LATIN AMERICA
  • 18.5.1 BRAZIL
    • 18.5.1.1 Adoption of non-animal testing methods to propel market
  • 18.5.2 MEXICO
    • 18.5.2.1 Ban on animal testing for cosmetics to support market growth
  • 18.5.3 REST OF LATIN AMERICA
• 18.6 MIDDLE EAST
  • 18.6.1 GCC COUNTRIES
    • 18.6.1.1 Saudi Arabia
      • 18.6.1.1.1 Rising pharmaceutical R&D activities and regulatory focus on alternative testing methods to support market growth
    • 18.6.1.2 United Arab Emirates (UAE)
      • 18.6.1.2.1 Expanding biotechnology ecosystem and growing focus on advanced safety assessment technologies supporting market growth
    • 18.6.1.3 Rest of GCC Countries
    • 18.6.1.4 Rest of Middle East
  • 18.6.2 AFRICA
    • 18.6.2.1 Precision medicine initiatives to fuel market growth

19 COMPETITIVE LANDSCAPE

• 19.1 OVERVIEW
• 19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET
• 19.3 REVENUE SHARE ANALYSIS
• 19.4 MARKET SHARE ANALYSIS
• 19.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 19.5.1 STARS
  • 19.5.2 EMERGING LEADERS
  • 19.5.3 PERVASIVE PLAYERS
  • 19.5.4 PARTICIPANTS
  • 19.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 19.5.5.1 Company footprint
    • 19.5.5.2 Region footprint
    • 19.5.5.3 Offering footprint
    • 19.5.5.4 Technology footprint
• 19.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 19.6.1 PROGRESSIVE COMPANIES
  • 19.6.2 STARTING BLOCKS
  • 19.6.3 RESPONSIVE COMPANIES
  • 19.6.4 DYNAMIC COMPANIES
  • 19.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS
    • 19.6.5.1 Competitive benchmarking of key startups/SMEs
• 19.7 COMPANY VALUATION & FINANCIAL METRICS
  • 19.7.1 FINANCIAL METRICS
  • 19.7.2 COMPANY VALUATION
• 19.8 BRAND/PRODUCT COMPARISON
• 19.9 COMPETITIVE SCENARIO
  • 19.9.1 PRODUCT LAUNCHES
  • 19.9.2 DEALS
  • 19.9.3 EXPANSIONS

20 COMPANY PROFILES

• 20.1 THERMO FISHER SCIENTIFIC INC.
  • 20.1.1 BUSINESS OVERVIEW
    • 20.1.1.1 Products/Services/Solutions offered
    • 20.1.1.2 Recent developments
      • 20.1.1.2.1 Product launches
      • 20.1.1.2.2 Deals
      • 20.1.1.2.3 Expansions
    • 20.1.1.3 MnM view
      • 20.1.1.3.1 Key strengths
      • 20.1.1.3.2 Strategic choices
      • 20.1.1.3.3 Weaknesses and competitive threats
  • 20.1.2 AGILENT TECHNOLOGIES, INC.
    • 20.1.2.1 Business overview
    • 20.1.2.2 Products/Services/Solutions offered
    • 20.1.2.3 Recent developments
      • 20.1.2.3.1 Product launches & enhancements
      • 20.1.2.3.2 Deals
    • 20.1.2.4 MnM view
      • 20.1.2.4.1 Key strengths
      • 20.1.2.4.2 Strategic choices
      • 20.1.2.4.3 Weaknesses and competitive threats
  • 20.1.3 MERCK KGAA
    • 20.1.3.1 Business overview
    • 20.1.3.2 Products/Services/Solutions offered
    • 20.1.3.3 Recent developments
      • 20.1.3.3.1 Deals
    • 20.1.3.4 MnM view
      • 20.1.3.4.1 Key strengths
      • 20.1.3.4.2 Strategic choices
      • 20.1.3.4.3 Weaknesses and competitive threats
  • 20.1.4 EUROFINS SCIENTIFIC
    • 20.1.4.1 Business overview
    • 20.1.4.2 Products/Services/Solutions offered
    • 20.1.4.3 Recent developments
      • 20.1.4.3.1 Expansions
  • 20.1.5 CHARLES RIVER LABORATORIES
    • 20.1.5.1 Business overview
    • 20.1.5.2 Products/Services/Solutions offered
    • 20.1.5.3 Recent developments
      • 20.1.5.3.1 Product launches
      • 20.1.5.3.2 Deals
      • 20.1.5.3.3 Other developments
    • 20.1.5.4 MnM view
      • 20.1.5.4.1 Key strengths
      • 20.1.5.4.2 Strategic choices
      • 20.1.5.4.3 Weaknesses and competitive threats
  • 20.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 20.1.6.1 Business overview
    • 20.1.6.2 Products/Services/Solutions offered
    • 20.1.6.3 Recent developments
      • 20.1.6.3.1 Deals
      • 20.1.6.3.2 Expansions
      • 20.1.6.3.3 Other developments
    • 20.1.6.4 MnM view
      • 20.1.6.4.1 Key strengths
      • 20.1.6.4.2 Strategic choices
      • 20.1.6.4.3 Weaknesses and competitive threats
  • 20.1.7 SGS SA
    • 20.1.7.1 Business overview
    • 20.1.7.2 Products/Services/Solutions offered
    • 20.1.7.3 Recent developments
      • 20.1.7.3.1 Deals
      • 20.1.7.3.2 Expansions
  • 20.1.8 LONZA
    • 20.1.8.1 Business overview
    • 20.1.8.2 Products/Services/Solutions offered
  • 20.1.9 REVVITY
    • 20.1.9.1 Business overview
    • 20.1.9.2 Products/Services/Solutions offered
    • 20.1.9.3 Recent developments
      • 20.1.9.3.1 Product launches
      • 20.1.9.3.2 Other developments
  • 20.1.10 BIO-RAD LABORATORIES, INC.
    • 20.1.10.1 Business overview
    • 20.1.10.2 Products/Services/Solutions offered
    • 20.1.10.3 Recent developments
      • 20.1.10.3.1 Product launches
      • 20.1.10.3.2 Deals
  • 20.1.11 EVOTEC SE
    • 20.1.11.1 Business overview
    • 20.1.11.2 Products/Services/Solutions offered
    • 20.1.11.3 Recent developments
      • 20.1.11.3.1 Deals
      • 20.1.11.3.2 Other developments
  • 20.1.12 NOVO HOLDINGS
    • 20.1.12.1 Business overview
    • 20.1.12.2 Products & services offered
  • 20.1.13 INTERTEK GROUP PLC
    • 20.1.13.1 Business overview
    • 20.1.13.2 Products & services offered
  • 20.1.14 INOTIV
    • 20.1.14.1 Business overview
    • 20.1.14.2 Products & services offered
  • 20.1.15 PROMEGA CORPORATION
    • 20.1.15.1 Business overview
    • 20.1.15.2 Products & services offered
    • 20.1.15.3 Recent developments
      • 20.1.15.3.1 Deals
• 20.2 OTHER PLAYERS
  • 20.2.1 BIOIVT
  • 20.2.2 CREATIVE BIOLABS
  • 20.2.3 MEDICILON
  • 20.2.4 CREATIVE BIOARRAY
  • 20.2.5 ARAGEN LIFE SCIENCES LTD.
  • 20.2.6 ENZO BIOCHEM INC.
  • 20.2.7 MICROBAC LABORATORIES, INC.
  • 20.2.8 VIMTA LABS LTD.
  • 20.2.9 PACIFIC BIOLABS, INC.
  • 20.2.10 MB RESEARCH LABORATORIES

21 RESEARCH METHODOLOGY

• 21.1 RESEARCH DATA
  • 21.1.1 SECONDARY DATA
  • 21.1.2 PRIMARY DATA
• 21.2 MARKET SIZE ESTIMATION
  • 21.2.1 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET ESTIMATION, 2025
    • 21.2.1.1 Key industry insights
• 21.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
• 21.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 21.5 RESEARCH ASSUMPTIONS
• 21.6 RESEARCH LIMITATIONS
• 21.7 RISK ANALYSIS

22 APPENDIX

• 22.1 DISCUSSION GUIDE
• 22.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 22.3 CUSTOMIZATION OPTIONS
• 22.4 RELATED REPORTS
• 22.5 AUTHOR DETAILS